ADENOSINE 3#,5#-CYCLIC MONOP 1PC X 10MG

Not available outside of the UK & Ireland.

Biochem/physiol Actions

Primary TargetProtein kinase A and protein kinase G

Reversible: no

Product does not compete with ATP.

Target IC₅₀: 900 nM against cGMP-specific phosphodiesterase

Cell permeable: yes

General description

Cell-permeable cAMP analog that activates both protein kinase A and protein kinase G. Induces the guanine-nucleotide-exchange factor activity of EGFI, also known as Epac (exchange protein directly activated by cAMP), and EGFII towards Rap1 both in vivo and in vitro. Also acts as a potent inhibitor of cGMP specific phosphodiesterase (IC₅₀ = 900 nM). Also inhibits cAMP-specific phosphodiesterases at much higher concentrations (IC₅₀ = 25 µM).

Cell-permeable cAMP analog that activates both protein kinase A and protein kinase G. Directly activates Epac, a Rap1 guanine-nucleotide exchange factor. Also acts as a potent inhibitor of cGMP-specific phosphodiesterase (IC₅₀ = 900 nM). Inhibits cAMP-specific phosphodiesterase at much higher concentrations (IC₅₀ = 25 µM).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

de Rooij, J., et al. 1998. Nature.396, 474.Kawasaki, H., et al. 1998. Science.282, 2275.Moed, P.J., et al. 1993. Comp. Biochem. Physiol.105A, 711.Connolly, B.J., et al. 1992. Biochem. Pharmacol.44, 2303.Phillips, M.E., and Taylor, A. 1992. J. Physiol.456, 591.Shipston, M.J., and Antoni, F.A. 1992. Endocrinology130, 2213.Datta, R., et al. 1991. Blood78, 83.Peters, D.J.M., et al. 1991. Proc. Natl. Acad. Sci. USA88, 9219.Sandberg, M., et al. 1991. Biochem. J.279, 521.Unterman, T.G., et al. 1991. Endocrinology128, 2693.Xu, H., et al. 1989. Brain Res.504, 36.

Packaging

10 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C

Warning

Toxicity: Standard Handling (A)